open access
99mTc-EDDA/HYNIC-TOC in management of patients with head and neck somatostatin receptor positive tumors
open access
Abstract
BACKGROUND: Aim of this study was to determine the value of technetium-99m-hydrazinonicotinyl-Tyr3-octreotide (99mTc-EDDA/HYNIC-TOC) in patients with somatostatin receptor (SSR) positive tumors of head and neck region.
MATERIAL AND METHODS: A total number of 16 patients were enrolled in this study. Planar whole body (WB) and single photon emission computed tomography (SPECT) images were acquired at 2 and 4 hours after the injection of approximately 670 MBq of 99mTc-EDDA/HYNIC-TOC. Additional single photon emission computed tomography/computed tomography (SPECT/CT) images of the head and neck region were acquired at 4h post tracer injection. Clinical and imaging follow up were taken as the reference standard.
RESULTS: There were 10 female and 6 male patients of age 57.7 ± 12.9 years (58.5; 32–78) years. 99mTc-EDDA/HYNIC-TOC somatostatin receptor scintigraphy (SRS) was TP in 13 patients, TN in two and FP in one. Follow up period for SRS was 31.1 ± 19.4 (29; 2–63) months. 99mTc-EDDA/HYNIC-TOC scintigraphy provided additional information in 50% of patients, with impact on patient management in the same percentage of patients. Distant metastases were found in nine out of 16 patients (56%). 99mTc-EDDA/HYNIC-TOC SRS had sensitivity of 100% (75.3–100%), specificity of 66.7% (9.4–99.2%), accuracy of 93.7%, positive predictive value of 92.9% (66.1–99.8%), and negative predictive value of 100% (15.8–100%).
CONCLUSION: Somatostatin receptor scintigraphy using 99mTc-EDDA/HYNIC-TOC is very useful imaging method in the evaluation of patients with SSR positive tumors of head and neck region.
Abstract
BACKGROUND: Aim of this study was to determine the value of technetium-99m-hydrazinonicotinyl-Tyr3-octreotide (99mTc-EDDA/HYNIC-TOC) in patients with somatostatin receptor (SSR) positive tumors of head and neck region.
MATERIAL AND METHODS: A total number of 16 patients were enrolled in this study. Planar whole body (WB) and single photon emission computed tomography (SPECT) images were acquired at 2 and 4 hours after the injection of approximately 670 MBq of 99mTc-EDDA/HYNIC-TOC. Additional single photon emission computed tomography/computed tomography (SPECT/CT) images of the head and neck region were acquired at 4h post tracer injection. Clinical and imaging follow up were taken as the reference standard.
RESULTS: There were 10 female and 6 male patients of age 57.7 ± 12.9 years (58.5; 32–78) years. 99mTc-EDDA/HYNIC-TOC somatostatin receptor scintigraphy (SRS) was TP in 13 patients, TN in two and FP in one. Follow up period for SRS was 31.1 ± 19.4 (29; 2–63) months. 99mTc-EDDA/HYNIC-TOC scintigraphy provided additional information in 50% of patients, with impact on patient management in the same percentage of patients. Distant metastases were found in nine out of 16 patients (56%). 99mTc-EDDA/HYNIC-TOC SRS had sensitivity of 100% (75.3–100%), specificity of 66.7% (9.4–99.2%), accuracy of 93.7%, positive predictive value of 92.9% (66.1–99.8%), and negative predictive value of 100% (15.8–100%).
CONCLUSION: Somatostatin receptor scintigraphy using 99mTc-EDDA/HYNIC-TOC is very useful imaging method in the evaluation of patients with SSR positive tumors of head and neck region.
Keywords
neuroendocrine tumors, receptors, somatostatin, tomography, emission-computed, single-photon, technetium 99m EDDA-HYNIC-Tyr (3)-octreotide
About this articleTitle
99mTc-EDDA/HYNIC-TOC in management of patients with head and neck somatostatin receptor positive tumors
Journal
Issue
Article type
Research paper
Pages
74-80
Published online
2016-07-29
Page views
2020
Article views/downloads
2065
DOI
Pubmed
Bibliographic record
Nucl. Med. Rev 2016;19(2):74-80.
Keywords
neuroendocrine tumors
receptors
somatostatin
tomography
emission-computed
single-photon
technetium 99m EDDA-HYNIC-Tyr (3)-octreotide
Authors
Mate Trogrlic
Stanko Tezak
